Mivebresib
Mivebresib (ABBV-075) is a potent and orally active bromodomain and extraterminal domain (BET) bromodomain inhibitor. Mivebresib binds to BRD4 with a Ki of 1.5 nM[1].
Product Specifications
CAS Number
1445993-26-9
Product Name Alternative
ABBV-075
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Apoptosis; Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Mivebresib.html
Purity
99.69
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
CCS(=O)(NC1=CC=C(OC2=CC=C(F)C=C2F)C(C3=CN(C)C(C4=C3C=CN4)=O)=C1)=O
Molecular Formula
C22H19F2N3O4S
Molecular Weight
459.47
Precautions
H315, H319, H335
References & Citations
[1]EJ Faivre et al. Abstract 4694: ABBV-075, a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
37819116 3x 1.0 µg
Prrg4 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat)
Sign In for Pricing
View Details 
OPCA04155-100UG 100 µg
IPAH9.8 Recombinant Protein (Shigella flexneri)
Sign In for Pricing
View Details RPC25784-01 20 µg
Recombinant Treponema pallidum Uncharacterized protein TP_0608 (TP_0608), partial
Sign In for Pricing
View Details